PWA
MCRB icon

Providence Wealth Advisors’s Seres Therapeutics MCRB Stock Holding History

Providence Wealth Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,250
Closed -$71.4K – 94
2025
Q1 		$71.4K Hold
5,250
– – 0.05% 81
2024
Q4 		$94K Buy
5,250
+325
+7% +$5.28K 0.07% 78
2024
Q3 		$76.8K Buy
4,925
+1,112
+29% +$22.6K 0.06% 80
2024
Q2 		$58K Buy
3,813
+1,263
+50% +$21.1K 0.05% 77
2024
Q1 		$38.6K Buy
2,550
+2,516
+7,400% +$54.3K 0.03% 79
2023
Q4 		$465K Buy
+34
New +$893 0.42% 59

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Providence Wealth Advisors's MCRB Position: Q2 2025 in Review

Providence Wealth Advisors sold out of Seres Therapeutics (MCRB) in Q2 2025, closing a stake of 5,250 shares — an estimated $71.4K sold.

Providence Wealth Advisors first reported a position in MCRB in Q4 2023 and held it in 6 quarters. The position peaked at $465K in Q4 2023. 33 funds tracked by Wall St. Rank hold MCRB as of Q2 2025.

  • Providence Wealth Advisors reported no remaining Seres Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Providence Wealth Advisors sold 5,250 Seres Therapeutics shares in Q2 2025, an estimated $71.4K.
  • Providence Wealth Advisors first reported a position in Seres Therapeutics in Q4 2023 and held it in 6 quarters.
  • Providence Wealth Advisors's Seres Therapeutics position peaked at $465K in Q4 2023.
  • 33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2025.

Based on Providence Wealth Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.